| 1 | 15:00-15:25 |
Opening Remarks |
|
|||||||||||||||||
| 1 | 15:25-15:45 |
From Evidence to Clinical Practice: Interpretation of the Expert Guidance on the Clinical Use of Enfortumab Vedotin in Urothelial Carcinoma |
|
|||||
| 2 | 15:45-16:05 |
Redefining First-Line Treatment: Enfortumab Vedotin Combination Therapy as a New SoC for La/mUC |
|
|||||
| 3 | 16:05-16:25 |
Redefining UC Care: Evolving Treatment Landscape and New Perspectives on Patient Management |
|
|||||
| 1 | 16:25-16:50 |
Discussion |
|
|||||||||||||||||||||||||||||||||||
| 1 | 16:50-17:10 |
Exploring current perceptions in mHSC: myths, evidence, and practice |
|
|||||
| 2 | 17:10-17:30 |
Shaping the Future: The Evolving Landscape of Prostate Cancer Treatment |
|
|||||
| 1 | 17:30-17:55 |
Discussion |
|
|||||||||||||||||||||||||||||
| 1 | 17:55-18:00 |
Summary |
|
||||||||||||||